|
1
|
Cancer Genome Atlas Research Network;
Albert Einstein College of Medicine; Analytical Biological
Services; Barretos Cancer Hospital; Baylor College of Medicine;
Beckman Research Institute of City of Hope; Buck Institute for
Research on Aging; Canada's Michael Smith Genome Sciences Centre;
Harvard Medical School, . Helen F, et al: Integrated genomic and
molecular characterization of cervical cancer. Nature. 543:378–384.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang K, Sun H, Li X, Hu T, Yang R, Wang
S, Jia Y, Chen Z, Tang F, Shen J, et al: Prognostic risk model
development and prospective validation among patients with cervical
cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy. Sci
Rep. 6:275682016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jadon R, Pembroke CA, Hanna CL,
Palaniappan N, Evans M, Cleves AE and Staffurth J: A systematic
review of organ motion and image-guided strategies in external beam
radiotherapy for cervical cancer. Clin Oncol (R Coll Radiol).
26:185–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
White A, Joseph D, Rim SH, Johnson CJ,
Coleman MP and Allemani C: Colon cancer survival in the United
States by race and stage (2001–2009): Findings from the CONCORD-2
study. Cancer. 123 (Suppl 24):S5014–S5036. 2017. View Article : Google Scholar
|
|
5
|
Obrzut B, Kusy M, Semczuk A, Obrzut M and
Kluska J: Prediction of 5-year overall survival in cervical cancer
patients treated with radical hysterectomy using computational
intelligence methods. BMC Cancer. 17:8402017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dunn J, Baborie A, Alam F, Joyce K, Moxham
M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, et al:
Extent of MGMT promoter methylation correlates with outcome in
glioblastomas given temozolomide and radiotherapy. Br J Cancer.
101:124–131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang KH, Huang SF, Chen IH, Liao CT, Wang
HM and Hsieh LL: Methylation of RASSF1A, RASSF2A, and HIN-1 is
associated with poor outcome after radiotherapy, but not surgery,
in oral squamous cell carcinoma. Clin Cancer Res. 15:4174–4180.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miousse IR, Kutanzi KR and Koturbash I:
Effects of ionizing radiation on DNA methylation: From experimental
biology to clinical applications. Int J Radiat Biol. 93:457–469.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Widschwendter A, Müller HH, Fiegl H,
Ivarsson L, Wiedemair A, Müller-Holzner E, Goebel G, Marth C and
Widschwendter M: DNA methylation in serum and tumors of cervical
cancer patients. Clin Cancer Res. 10:565–571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okayama H, Schetter AJ, Ishigame T, Robles
AI, Kohno T, Yokota J, Takenoshita S and Harris CC: The expression
of four genes as a prognostic classifier for stage I lung
adenocarcinoma in 12 independent cohorts. Cancer Epidemiol
Biomarkers Prev. 23:2884–2894. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng SH, Horng CF, Huang TT, Huang ES,
Tsou MH, Shi LS, Yu BL, Chen CM and Huang AT: An eighteen-gene
classifier predicts locoregional recurrence in post-mastectomy
breast cancer patients. EBioMedicine. 5:74–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harbour JW: A prognostic test to predict
the risk of metastasis in uveal melanoma based on a 15-gene
expression profile. Methods Mol Biol. 1102:427–440. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Field MG, Decatur CL, Kurtenbach S, Gezgin
G, van der Velden PA, Jager MJ, Kozak KN and Harbour JW: PRAME as
an independent biomarker for metastasis in Uveal melanoma. Clin
Cancer Res. 22:1234–1242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee YY, Kim TJ, Kim JY, Choi CH, Do IG,
Song SY, Sohn I, Jung SH, Bae DS, Lee JW and Kim BG: Genetic
profiling to predict recurrence of early cervical cancer. Gynecol
Oncol. 131:650–654. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang P, Wang Y, Hang B, Zou X and Mao JH:
A novel gene expression-based prognostic scoring system to predict
survival in gastric cancer. Oncotarget. 7:55343–55351.
2016.PubMed/NCBI
|
|
16
|
Goeman JJ: L1 penalized estimation in the
Cox proportional hazards model. Biom J. 52:70–84. 2010.PubMed/NCBI
|
|
17
|
Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng
Z, Zhu G, Qi J, Ma H, Nian H and Wang Y: RNA-seq analyses of
multiple meristems of soybean: Novel and alternative transcripts,
evolutionary and functional implications. BMC Plant Biol.
14:1692014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu FF, Shi W, Done SJ, Miller N, Pintilie
M, Voduc D, Nielsen TO, Nofech-Mozes S, Chang MC, Whelan TJ, et al:
Identification of a Low-Risk luminal a breast cancer cohort that
may not benefit from breast radiotherapy. J Clin Oncol.
33:2035–2040. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang XM, Sheng SR, Wang XY, Bin LH, Wang
JR and Li GY: Expression of tumor related gene NAG6 in gastric
cancer and restriction fragment length polymorphism analysis. World
J Gastroenterol. 10:1361–1364. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gupta N, Martin PM, Miyauchi S, Ananth S,
Herdman AV, Martindale RG, Podolsky R and Ganapathy V:
Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.
Biochem Biophys Res Commun. 343:571–577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Osanai M and Lee GH: Increased expression
of the retinoic acid-metabolizing enzyme CYP26A1 during the
progression of cervical squamous neoplasia and head and neck
cancer. BMC Res Notes. 7:6972014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Downie D, Mcfadyen MC, Rooney PH,
Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT and
Murray GI: Profiling cytochrome P450 expression in ovarian cancer:
Identification of prognostic markers. Clin Cancer Res.
11:7369–7375. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang D, Li T, Cui H and Zhang Y: Analysis
of the indicating value of cardiac troponin I, tumor necrosis
factor-α, interleukin-18, Mir-1 and Mir-146b for viral myocarditis
among Children. Cell Physiol Biochem. 40:1325–1333. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kern BE, Balcom JH, Antoniu BA, Warshaw AL
and Fernández-del Castillo C: Troponin I peptide (Glu94-Leu123), a
cartilage-derived angiogenesis inhibitor: In vitro and in vivo
effects on human endothelial cells and on pancreatic cancer. J
Gastrointest Surg. 7:961–969. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Casas-Tintó S, Maraver A, Serrano M and
Ferrús A: Troponin-I enhances and is required for oncogenic
overgrowth. Oncotarget. 7:52631–52642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei S, Shang H, Cao Y and Wang Q: The
coiled-coil domain containing protein Ccdc136b antagonizes maternal
Wnt/β-catenin activity during zebrafish dorsoventral axial
patterning. J Genet Genomics. 43:431–438. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kopczynski J, Kowalik A, Chłopek M, Wang
ZF, Góźdź S, Lasota J and Miettinen M: Oncogenic activation of the
Wnt/β-catenin signaling pathway in signet ring stromal cell tumor
of the ovary. Appl Immunohistochem Mol Morphol. 24:e28–e33. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nagaraj AB, Joseph P, Kovalenko O, Singh
S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S and
DiFeo A: Critical role of Wnt/β-catenin signaling in driving
epithelial ovarian cancer platinum resistance. Oncotarget.
6:23720–23734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Emons G, Spitzner M, Reineke S, Auslander
N, Kramer F, Rave-Fraenk M, Gaedcke J, Ghadimi M, Ried T and Grade
M: Abstract 4760: Wnt/β-catenin signaling mediates resistance of
colorectal cancer cell lines to chemoradiotherapy. Cancer Res.
77:4760. 2017.
|
|
34
|
Lan K, Zhao Y, Fan Y, Ma B, Yang S, Liu Q,
Linghu H and Wang H: Sulfiredoxin may promote cervical cancer
metastasis via Wnt/β-catenin signaling pathway. Int J Mol Sci.
18(pii): E9172017.PubMed/NCBI
|
|
35
|
Sarkadi B, Ozvegy-Laczka C, Német K and
Váradi A: ABCG2-a transporter for all seasons. FEBS Lett.
567:116–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elkind NB, Szentpétery Z, Apáti A,
Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A,
Buday L, et al: Multidrug transporter ABCG2 prevents tumor cell
death induced by the epidermal growth factor receptor inhibitor
Iressa (ZD1839, Gefitinib). Cancer Res. 65:1770–1777. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chau WK, Ip CK, Mak AS, Lai HC and Wong
AS: c-Kit mediates chemoresistance and tumor-initiating capacity of
ovarian cancer cells through activation of
Wnt/β-catenin-ATP-binding cassette G2 signaling. Oncogene.
32:2767–2781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu HG, Pan YF, You J, Wang OC, Huang KT
and Zhang XH: Expression of ABCG2 and its significance in
colorectal cancer. Asian Pac J Cancer Prev. 11:845–848.
2010.PubMed/NCBI
|
|
39
|
Sari FM, Yanar HT and Ozhan G:
Investigation of the functional single-nucleotide polymorphisms in
the BCRP transporter and susceptibility to colorectal cancer.
Biomed Rep. 3:105–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Turner JG, Gump JL, Zhang C, Cook JM,
Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS and
Sullivan DM: ABCG2 expression, function, and promoter methylation
in human multiple myeloma. Blood. 108:3881–3889. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bram EE, Stark M, Raz S and Assaraf YG:
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a
novel mechanism of acquired multidrug resistance 1 2. Neoplasia.
11:1359–1370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang CL, Hong E, Lao-Sirieix P and
Fitzgerald RC: A novel role for the retinoic acid-catabolizing
enzyme CYP26A1 in Barrett's associated adenocarcinoma. Oncogene.
27:2951–2960. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang XH and Gudas LJ: Retinoids, retinoic
acid receptors, and cancer. Annu Rev Pathol. 6:345–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huang GL, Luo Q, Rui G, Zhang W, Zhang QY,
Chen QX and Shen DY: Oncogenic activity of retinoic acid receptor γ
is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin
pathways in cholangiocarcinoma. Mol Cell Biol. 33:3416–3425. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yasuhara R, Yuasa T, Williams JA, Byers
SW, Shah S, Pacifici M, Iwamoto M and Enomoto-Iwamoto M:
Wnt/beta-catenin and retinoic acid receptor signaling pathways
interact to regulate chondrocyte function and matrix turnover. J
Biol Chem. 285:317–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Francesca C, Stefano R, Gaia B, Ren M and
Nicoletta S: Derangement of a factor upstream of RARalpha triggers
the repression of a pleiotropic epigenetic network. PLoS One.
4:e43052009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu LY: Association of tissue promoter
methylation levels of APC, RASSF1A, CYP26A1 and TBX15 with prostate
cancer progression (unpublished PhD thesis)University of Toronto
(Canada); 2012
|
|
48
|
García-Mariscal A, Peyrollier K, Basse A,
Pedersen E, Rühl R, van Hengel J and Brakebusch C: RhoA controls
retinoid signaling by ROCK dependent regulation of retinol
metabolism. Small GTPases. 9:433–444. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH,
Chang YW, Chen YH, Jan Y, Hsiao M, Chang TY, et al:
MiR-520h-mediated FOXC2 regulation is critical for inhibition of
lung cancer progression by resveratrol. Oncogene. 32:431–443. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zheng CH, Quan Y, Li YY, Deng WG, Shao WJ
and Fu Y: Expression of transcription factor FOXC2 in cervical
cancer and effects of silencing on cervical cancer cell
proliferation. Asian Pac J Cancer Prev. 15:1589–1595. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhou Z, Zhang L, Xie B, Wang X, Yang X,
Ding N, Zhang J, Liu Q, Tan G, Feng D and Sun LQ: FOXC2 promotes
chemoresistance in nasopharyngeal carcinomas via induction of
epithelial mesenchymal transition. Cancer Lett. 363:137–145. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Martens S, Kozlov MM and Mcmahon HT: How
synaptotagmin promotes membrane fusion. Science. 316:1205–1208.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Geppert M, Goda Y, Hammer RE, Li C, Rosahl
TW, Stevens CF and Südhof TC: Synaptotagmin I: A major Ca2+ sensor
for transmitter release at a central synapse. Cell. 79:717–727.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jahn JE and Coleman WB: Phenotypic
normalization of GN6TF rat liver tumor cells results from WT1
expression following transfection of human SYT13-containing BACs.
FASEB J. 20:A10912006.
|
|
55
|
Kanda M, Shimizu D, Tanaka H, Tanaka C,
Kobayashi D, Hayashi M, Iwata N, Niwa Y, Yamada S, Fujii T, et al:
Significance of SYT8 For the detection, prediction, and treatment
of peritoneal metastasis from gastric cancer. Ann Surg.
267:495–503. 2016. View Article : Google Scholar
|
|
56
|
Sung HY, Han J, Ju W and Ahn JH:
Synaptotagmin-like protein 2 gene promotes the metastatic potential
in ovarian cancer. Oncol Rep. 36:535–541. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Jin H, Xu G, Zhang Q, Pang Q and Fang M:
Synaptotagmin-7 is overexpressed in hepatocellular carcinoma and
regulates hepatocellular carcinoma cell proliferation via Chk1-p53
signaling. Onco Targets Ther. 10:4283–4293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kanda M, Shimizu D, Tanaka H, Tanaka C,
Kobayashi D, Hayashi M, Takami H, Niwa Y, Yamada S, Fujii T, et al:
Synaptotagmin XIII expression and peritoneal metastasis in gastric
cancer. Br J Surg. 105:1349–1358. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li A, King J, Moro A, Sugi MD, Dawson DW,
Kaplan J, Li G, Lu X, Strieter RM, Burdick M, et al: Overexpression
of CXCL5 is associated with poor survival in patients with
pancreatic cancer. Am J Pathol. 178:1340–1349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Park JY, Park KH, Bang S, Kim MH, Lee JE,
Gang J, Koh SS and Song SY: CXCL5 overexpression is associated with
late stage gastric cancer. J Cancer Res Clin Oncol. 133:835–840.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kawamura M, Toiyama Y, Tanaka K, Saigusa
S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M:
CXCL5, a promoter of cell proliferation, migration and invasion, is
a novel serum prognostic marker in patients with colorectal cancer.
Eur J Cancer. 48:2244–2251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Begley L, Kasina S, Mehra R, Adsule S,
Admon AJ, Lonigro RJ, Chinnaiyan AM and Macoska JA: CXCL5 promotes
prostate cancer progression. Neoplasia. 10:244–254. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang C, Li A, Yang S, Qiao R, Zhu X and
Zhang J: CXCL5 promotes mitomycin C resistance in non-muscle
invasive bladder cancer by activating EMT and NF-κB pathway.
Biochem Biophys Res Commun. 498:862–868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Guan Z, Li C, Fan J, He D and Li L:
Androgen receptor (AR) signaling promotes RCC progression via
increased endothelial cell proliferation and recruitment by
modulating AKT→NF-κB→CXCL5 signaling. Sci Rep. 6:370852016.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16:702017. View Article : Google Scholar : PubMed/NCBI
|
